结直肠癌肝转移新辅助化疗的共识与争议.ppt
《结直肠癌肝转移新辅助化疗的共识与争议.ppt》由会员分享,可在线阅读,更多相关《结直肠癌肝转移新辅助化疗的共识与争议.ppt(77页珍藏版)》请在第壹文秘上搜索。
1、结直肠癌肝转移新辅助结直肠癌肝转移新辅助化疗的共识与争议化疗的共识与争议Epidemiology of colorectal cancer(CRC)Results of Hepatic Resection for Metastatic Colorectal CancerLiver metastases of CRCManagement of MCRC:An Evolving Treatment Algorithm Neoadj:where is the most controversyConcept of resectability手术的关注重点由手术的关注重点由“哪些可以切除哪些可以切除”转
2、变为转变为“哪些可以保留哪些可以保留”Timothy M.Pawlik 2008只要能够完全切除,转移灶的个数与长期生存率无关只要能够完全切除,转移灶的个数与长期生存率无关Altendorf-Hofmann A,Scheele J.A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma.Surg Oncol Clin N Am 2003;12:165192 No.of met and resectability(A
3、):(A):不完全性切除患者的不完全性切除患者的MSTMST只有只有 14 14 月,而完全切除患者的月,而完全切除患者的MSTMST为为44 44 月。月。Altendorf-Hofmann A,et al.Surg Oncol Clin N Am 2003;12:165192.(B):只要能够完全切除,切除边界只要能够完全切除,切除边界的宽度对生存时间无明显影响。的宽度对生存时间无明显影响。Pawlik TM,et al.Effect of surgical margin status on survival and site of recurrence after hepatic res
4、ection for colorectal metastases.Ann Surg 2005;241:715722;discussion 722724Margin and resectability Neoadjuvant chemotherapy for resectable liver metastases of CRC resectablePreoperative chemotherapywhat are possible benefits?Tumor shrinkage may facilite resection whith a hope for higher survival ra
5、tes Test chemoresponsiveness of matastases Select candidates for resection -Exclude tumors progressing while on chemotherapy -Be more aggressive on responding tumorsEORTC 40983:Peri-operative chemotherapySize of lesions after pre-op chemotherapyPhase 3 Trial of Perioperative FOLFOX4 and Surgery for
6、Resectable CRC Liver Metastases(EORTC 40983):PFSRationale AGAINST neoadjuvant CT Risk that metastases become unresectable if they progress during chemotherapy Uncertainty about how to deal with“complete response”to chemotherapy Liver damage induced by chemotherapyPreoperative chemotherapy:potential
7、problems Lost window of opportunity Tumor growth in a critical area may render metastases unresectable Chemotherapy induced portal vein thrombosis 1.Donadon M,et al.W J Gastroenteral 12:6556,2006Survival according to response to neoadjuvant chemotherapy ATE:cerebral infact,myocardial infarction,TIA,
8、angina Risk factors for developing ATE Age 65 y(P=0.01)Prior history of ATE(P 4.5 cm Residual tumor identified:83%Chemotherapy reduces sensitivity of PET detection of matastases2,31.Benoist S,et al,J Clin Oncol 24:3939,20062.Akhurst T,et al,J Clin Oncol 23:8713,20053.Tan,MCB et al,J Gastrointest Sur
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 直肠癌 转移 辅助 化疗 共识 争议